Status
Conditions
Treatments
About
This is a randomized crossover-designed study to explore the immunologic effects of Prebiotics, as opposed to direct supplementation with beneficial bacteria (Probiotics) in the immune system of patients with MS and Clinically Isolated Syndrome (CIS). Eligible patients will take 6 weeks of two different supplements - Prebiotics and Probiotics. Participants will be randomly assigned to take either of two agents for 6 weeks as their first supplement. Then, participants enter a 6-week washout period. After the washout period, participants will take the second supplement for 6 weeks. After taking the second supplement, participants will have a 6-week washout period.
Full description
Soluble fibers (prebiotics) are fermented by beneficial bacteria (probiotics) in the colon to produce short-chain fatty acids (SCFAs) which are the main source of nutrition for the cells in the gut. It has been reported that the fermentable fiber inulin and SCFAs may exert some beneficial effects including anti-inflammatory effect on the immune system. To date, the effect of supplementation with fermentable dietary fiber, such as prebiotics in patients with Multiple Sclerosis (MS) has not been investigated.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Active relapse within 3 months of enrollment
Steroid use within 4 weeks of enrollment
Antibiotics use within 3 months of enrollment
Daily pre or prebiotic use within 3 months of enrollment
Diagnosed with any of the autoimmune disorders: Rheumatoid Arthritis, Lupus, Celiac disease, Vitiligo, Psoriasis, Psoriatic Arthritis, Hashimoto's Thyroiditis, Graves' Disease, Sjogren's syndrome, Type 1 Diabetes, Scleroderma, Crohn's Disease, Ulcerative Colitis, Alopecia Areata.
Had surgery of the GI tract in the last 5 years (with the exception of cholecystectomy and appendectomy)
Had a major bowel resection
Prior use of any of the following drugs: Mycophenolate/Cellcept, Cyclophosphamide/Cytoxan, Methotrexate/Novantrone, Azathioprine/Imuran, Cladribine/Leustatin/Mavenclad, Daclizumab/Zenepax, Alemtuzumab/Campath/Lemtrada
Have any of the following active uncontrolled gastrointestinal (GI) illnesses:
Active use of bismuth subsalicylate-containing products
Currently pregnant
Primary purpose
Allocation
Interventional model
Masking
37 participants in 2 patient groups
Loading...
Central trial contact
Rebecca Farber, MD; Kaho Onomichi, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal